Close Menu

This article has been updated from a previous version to clarify statements made by an Agilent executive. 

NEW YORK – Agilent Technologies' planned $695 million acquisition of liquid biopsy startup Resolution Biosciences, announced earlier this week, is expected to provide the firm with immediate access to the next-generation sequencing (NGS)-based liquid biopsy market.

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try 360Dx Premium now.

You may already have institutional access!

Check if I qualify.

Already a 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.